Investor Relations

Deciphera Pharmaceuticals (DCPH) is a biopharmaceutical company focused on discovering, developing, and delivering important new medicines to patients for the treatment of cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to execute our strategy to develop a broad portfolio of innovative medicines. We have one approved drug, QINLOCK®, and we are developing two clinical-stage drug candidates. In addition, our drug discovery teams are working on new targets to develop the next generation of cancer medicines.